ID   THP-1/ara-C
AC   CVCL_4V22
DR   cancercelllines; CVCL_4V22
DR   Wikidata; Q54972341
RX   PubMed=21290089;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC   Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9163; Childhood acute monocytic leukemia
DI   ORDO; Orphanet_514; Acute monoblastic/monocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0006 ! THP-1
SX   Male
AG   1Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=21290089; DOI=10.3892/ijo.2011.933;
RA   Negoro E., Yamauchi T., Urasaki Y., Nishi R., Hori H., Ueda T.;
RT   "Characterization of cytarabine-resistant leukemic cell lines
RT   established from five different blood cell lineages using gene
RT   expression and proteomic analyses.";
RL   Int. J. Oncol. 38:911-919(2011).
//